Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Astellas Pharma Inc.
DescriptionAntibody-drug conjugate (ADC) targeting phosphodiesterase-I beta (ENPP3; NPP3; CD203c)
Molecular Target Phosphodiesterase-I beta (ENPP3) (NPP3) (CD203c)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I
Standard IndicationRenal cancer
Indication DetailsTreat metastatic renal cancer
Regulatory Designation
PartnerSeattle Genetics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today